Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06793943 · ClinicalTrials.gov registry record · Phase 1
A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT06793943 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 78 participants.
The verdict
NCT06793943, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
The main aim of this study is to find out how zasocitinib (TAK-279) interacts with other medicines taken by mouth (orally). This will be examined by how the body processes medicines, which is called pharmacokinetics or PK. In this study, other medicines that will be administered together with zasocitinib include a contraceptive (levonorgestrel (LNG) and ethinyl estradiol \[EE\]), a medicine for diabetes (metformin), a medicine used for heart problems (digoxin), and a medicine that blocks the production of stomach acid (esomeprazole). Another aim is to learn about the side effects of zasocitinib and how well it is tolerated when taken alone and together with these other medicines. During the study, participants will need to stay at the clinic for up to 27 days.
Interventions
- DRUG Metformin
- DRUG Esomeprazole
- DRUG Zasocitinib
- DRUG Digoxin
- DRUG COC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2025-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06793943
The ClinicalTrials.gov registry entry for NCT06793943 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT06793943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06793943 about?
NCT06793943 is a clinical study titled "A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults". The main aim of this study is to find out how zasocitinib (TAK-279) interacts with other medicines taken by mouth (orally). This will be examined by how the body processes medicines, which is called pharmacokinetics or PK. In this study, other medicines that will be administered together with zasoci...
What is the current status of trial NCT06793943?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2025-01-23. Estimated completion is 2025-03-30.
What interventions are being tested in trial NCT06793943?
The interventions under investigation include: Metformin (DRUG), Esomeprazole (DRUG), Zasocitinib (DRUG), Digoxin (DRUG), COC (DRUG).
Who is sponsoring clinical trial NCT06793943?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.